Querying the CAS Content Collection for publications related to CRISPR and it's role in therapeutic treatment, therapeutic development and therapeutic discovery (shortened to CRISPR therapeutics in this manuscript), while filtering out all agriculture related documents (see Methods section for query and details), resulted in over 39,000 academic journal articles and over 14,000 patents spanning from 1995 to June 2024. Publications on this topic sharply rose in 2008 and have steadily increased ever since with an average growth rate of 54% in the last decade (2014-2023) (Figure ). This total rise in publications is primarily led by academic journal articles; however, patents showed a larger average yearly growth rate of 72% in the last decade when compared to journals (50%), demonstrating an increase in commercial interest. We identified the top 100 journals containing the largest number CRISPR therapeutics documents between 1995 and 2024. We then filtered out of this set the journals with the highest average citation per publication to provide Figure . The journal Science, with 262 publications, has the highest average citation (253 citations/publication) out of the top 100 journals by total publication (Figure ). Topics of recently published and highly cited articles from this journal explore: the use of CRISPR/Cas9 screens to identify genes that could protect against copperinduced cell killing; 87 the development of astrocyte-specific CRISPR/Cas9-based gene knockdown to reduce the expression of astrocyte morphology genes related to of Alzheimer's disease risk and other central nervous systems disorders; and the combination of fluorescence image-enabled cell sorting with CRISPR-pooled screens to identify regulators of the nuclear factor κB (NF-κB) pathway, quickly completing genome-wide image-based screens (9 hours). Cell, the most known and oldest journal under Cell Press, comes in second place when it comes to citations with 220 citations/publications and 258 publications. Two recent publications in this journal with a high number of citations discuss the development and application of engineered DNA-free virus-like particles that efficiently package and deliver base editor or Cas9 ribonucleoproteins in vivo by overcoming cargo packaging, release, and localization bottlenecks; and the use of genome-scale Perturb-seq targeting all expressed genes with CRISPRi across >2.5 million human cells for the generation of information-rich genotypephenotype maps. Out of the top 15 journals shown in Figure , seven are owned by Springer Nature. The journals Nature Biotechnology, with a total of 353 publications, and Nature, with a total of 486 publications, come in third and fourth place with 161 citations/publication and 124 citations/publication respectively. In addition, our data also shows that Nature Communications is the journal with the most publications on the topic of CRISPR therapeutics with 1220 publications (Figure ). Examples from Nature Biotechnology discuss things like: the design of an optimized Un1Cas12f1 and its application as a miniature CRISPR system that fits into the adeno-associated virus, new technologies to address challenges and allow biologically targeted mRNA therapeutics, and a prime editing-based method that achieves higher precision than CRISPR-Cas9 and sgRNA pairs in programming genomic deletions. Some examples of recent highly cited publications from the journal Nature use CRISPR to conduct a genome-wide CRISPR knockout screen in glioblastoma to systematically identify potential resistance pathways to CAR T cell cytotoxicity in solid tumors, use CRISPR-mediated targeting to identify mediators of Hopx induction (a transcriptional regulator) by β-hydroxybutyrate (BHB) and identify a BHB-triggered pathway regulating intestinal tumorigenesis, and provide molecular insight into the underlying structural mechanisms that cause off-target effects of Cas9 and a proof of concept for the design of Cas9 variants that reduce off-target DNA cleavage while retaining efficient cleavage of ontarget DNA. We then took a look at which organizations are leading academic research in the field of CRISPR Therapeutics. If only taking into consideration number of publications (Figure ), the University of California, the Chinese Academy of Sciences, and Harvard University take the lead. Combination of research output (number of journal publications) and its impact (average citation per publication) reveals a different list (Figure ) with Massachusetts General Hospital, Massachusetts Institute of Technology (MIT) and Harvard University as the leaders. Analyzing the geographical distribution of these leading organizations indicate that a majority of them originate in the United States (Figure ). To gain further insight into what these 3 organizations are researching we looked at some examples of recent publications.